Matthew I Ebia
Research Subjects
Research Interests
Matthew I Ebia has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Anishka D'Souza
Division of Oncology, University of Southern California - Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, USA
1 shared publication- Charité Ricker
Keck School of Medicine, University of Southern California, Los Angeles, USA
1 shared publication - David Robert Freyer
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA
1 shared publication - Gino Kim In
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA
1 shared publication - Irene Kang
University of Southern California
1 shared publication - Jacob Thomas
Division of Medical Oncology, Department of Medicine, University of Southern California (USC), Los Angeles, CA
1 shared publication
Latest Publications
- Open Access
- 6 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15480
A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
Multiple primary malignancies (MPM) are described as two or more primary tumors within the same individual. The impact of MPM on the tumor microenvironment among patients with melanoma is poorly understood. Here, we describe this unique group of patients who have both advanced melanoma and at least one other primary malignancy and report their survival outcomes. In this study, patients with advanced melanoma and a second primary malignancy were identified. Medical records were reviewed for cancer treatment history. Kaplan-Meier methods were used to derive survival curves and estimate overall survival (OS), and log-rank tests were used to compare OS. Among 11 MPM patients, the most common non-melanoma cancers were breast (n = 3) and thyroid (n = 3). Median OS was 153.5 months for all patients. Median OS for synchronous MPM (sMPM) and metachronous MPM (mMPM) were 83.1 and 196.7 months, respectively (p = 0.10). Median OS was not reached when melanoma was diagnosed first, and 153.5 months when diagnosed second (p = 0.45). For six patients receiving immunotherapy for melanoma, there was a 100% complete response rate. In conclusion, patients with melanoma are at risk of secondary malignancies, including breast and thyroid cancer. The timing of secondary malignancies may impact prognosis. Further study of the impact of immunotherapy on MPM is warranted.
- 6 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15480
Open AccessA Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
Multiple primary malignancies (MPM) are described as two or more primary tumors within the same individual. The impact of MPM on the tumor microenvironment among patients with melanoma is poorly understood. Here, we describe this unique group of patients who have both advanced melanoma and at least one other primary malignancy and report their survival outcomes. In this study, patients with advanced melanoma and a second primary malignancy were identified. Medical records were reviewed for cancer treatment history. Kaplan-Meier methods were used to derive survival curves and estimate overall survival (OS), and log-rank tests were used to compare OS. Among 11 MPM patients, the most common non-melanoma cancers were breast (n = 3) and thyroid (n = 3). Median OS was 153.5 months for all patients. Median OS for synchronous MPM (sMPM) and metachronous MPM (mMPM) were 83.1 and 196.7 months, respectively (p = 0.10). Median OS was not reached when melanoma was diagnosed first, and 153.5 months when diagnosed second (p = 0.45). For six patients receiving immunotherapy for melanoma, there was a 100% complete response rate. In conclusion, patients with melanoma are at risk of secondary malignancies, including breast and thyroid cancer. The timing of secondary malignancies may impact prognosis. Further study of the impact of immunotherapy on MPM is warranted.